PMID- 24021344
OWN - NLM
STAT- MEDLINE
DCOM- 20140917
LR  - 20220408
IS  - 1879-0887 (Electronic)
IS  - 0167-8140 (Linking)
VI  - 109
IP  - 1
DP  - 2013 Oct
TI  - Reduction of the treated volume to involved node radiation therapy as part of 
      combined modality treatment for early stage aggressive non-Hodgkin's lymphoma.
PG  - 133-9
LID - S0167-8140(13)00388-5 [pii]
LID - 10.1016/j.radonc.2013.07.013 [doi]
AB  - BACKGROUND AND PURPOSE: This retrospective study investigated whether focused 
      involved node radiation therapy (INRT) can safely replace involved field RT 
      (IFRT) in patients with early stage aggressive NHL. PATIENTS AND METHODS: We 
      included 258 patients with stage I/II aggressive NHL who received combined 
      modality treatment (87%) or primary RT alone (13%). RT consisted of a total dose 
      of 30-40 Gy in 15-20 fractions IFRT or INRT. We compared survival, relapse 
      pattern, radiation-related toxicity and quality of life for both RT techniques. 
      RESULTS: Type of RT was not related to the outcome in either the uni- or 
      multivariate survival analysis. Relapses developed in 59 of 252 patients (23%) of 
      which 47 (80%) were documented as distant recurrence only. Failure of the INRT 
      technique was noted in one patient. There was no significant difference in acute 
      radiation-related toxicity between RT-groups but IFRT showed a significantly 
      higher incidence of higher grade toxicities. Patients treated with INRT had a 
      significantly better physical functioning and global quality of life compared to 
      the IFRT group. CONCLUSIONS: Given the retrospective nature of this study, no 
      solid conclusions can be drawn. However, in view of the equivalent efficacy and 
      more favorable toxicity profile, the replacement of IFRT by INRT in combination 
      with chemo-(immuno)-therapy looks very attractive for patients with early stage 
      aggressive NHL.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Verhappen, Marieke H
AU  - Verhappen MH
AD  - Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands.
FAU - Poortmans, Philip M P
AU  - Poortmans PM
FAU - Raaijmakers, Esther
AU  - Raaijmakers E
FAU - Raemaekers, John M M
AU  - Raemaekers JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130907
PL  - Ireland
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic 
      Radiology and Oncology
JID - 8407192
SB  - IM
MH  - Adult
MH  - Aged
MH  - Combined Modality Therapy
MH  - Female
MH  - Heart/radiation effects
MH  - Humans
MH  - Lymph Nodes/*radiation effects
MH  - Lymphoma, Non-Hodgkin/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Chemotherapy
OT  - Involved field radiation therapy
OT  - Involved node radiation therapy
OT  - Malignant lymphoma
OT  - Non-Hodgkin's lymphoma
EDAT- 2013/09/12 06:00
MHDA- 2014/09/18 06:00
CRDT- 2013/09/12 06:00
PHST- 2012/11/29 00:00 [received]
PHST- 2013/06/30 00:00 [revised]
PHST- 2013/07/16 00:00 [accepted]
PHST- 2013/09/12 06:00 [entrez]
PHST- 2013/09/12 06:00 [pubmed]
PHST- 2014/09/18 06:00 [medline]
AID - S0167-8140(13)00388-5 [pii]
AID - 10.1016/j.radonc.2013.07.013 [doi]
PST - ppublish
SO  - Radiother Oncol. 2013 Oct;109(1):133-9. doi: 10.1016/j.radonc.2013.07.013. Epub 
      2013 Sep 7.